Clinical Trial Update: Long-Term Study of IGIV, 10% in Alzheimer´s Disease [Phase 3]

View source ↗

Summary

Phase 3 long-term study of 10% intravenous immunoglobulin (IGIV) in Alzheimer's disease was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• IGIV 10%

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alzheimer´s Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-08-23